CJC-1295 (No DAC) vs PT-141: Mechanism, Half-Life & Research Use

Direct Comparison: CJC-1295 (No DAC) vs PT-141 Overview

CJC-1295 (No DAC) and PT-141 differ fundamentally in receptor targets and signaling pathways. CJC-1295 (No DAC) is a 29-amino-acid GHRH analog that activates pituitary GHRH receptors to stimulate endogenous growth hormone (GH) secretion. Conversely, PT-141 is a cyclic peptide derivative of alpha-MSH that binds central melanocortin receptors (MC3R/MC4R) to modulate central nervous system behavioral pathways.

Because these two compounds operate through non-overlapping endocrine and neurochemical axes, researchers must select between them based on whether their experimental model focuses on somatotropic signaling or central melanocortinergic receptor activity. While both compounds are widely evaluated in preclinical literature, their structural designs, plasma half-lives, and downstream physiological targets do not intersect.

Labelled Criteria Comparison Table

To assist laboratory personnel in protocol development, the table below provides a side-by-side technical breakdown of key pharmacological criteria for both research peptides.

| Criteria | CJC-1295 (No DAC) | PT-141 (Bremelanotide) | | :--- | :--- | :--- | | **Mechanistic Class** | GHRH Receptor Agonist | Central Melanocortin Agonist | | **Primary Receptor Target** | GHRH Receptor (Pituitary) | MC3R & MC4R (CNS) | | **Reported In Vivo Half-Life** | ~30 minutes | ~1.5 to 2 hours | | **Chemical Structure** | Linear 29-amino-acid peptide | Cyclic heptapeptide derivative | | **Solubility Profile** | High solubility in sterile/bacteriostatic water | Soluble in sterile/bacteriostatic water | | **Typical Preclinical Model** | Rodent somatotropic & tissue repair models | Rodent CNS behavioral & vascular models | | **Standard Vial Sizes** | 2mg, 5mg lyophilisate | 10mg lyophilisate |

This structural and operational divergence dictates how each material must be handled, reconstituted, and quantified within controlled laboratory setups. For comprehensive catalog options, explore our complete list of all peptides for lab investigation.

Molecular Structure & Synthesis of CJC-1295 (No DAC)

CJC-1295 (No DAC)—also known in scientific literature as Modified GRF 1-29—is a synthetic tetrasubstituted peptide derivative of endogenous growth hormone-releasing hormone (GHRH). Endogenous GHRH consists of 44 amino acids, but functional activity resides within the first 29 residues. Native GHRH 1-29 (sermorelin) is rapidly degraded in blood plasma by the enzyme dipeptidyl peptidase IV (DPP-IV), yielding an extremely short biological half-life of less than 12 minutes.

To improve enzymatic stability, chemists substituted four amino acids at positions 2, 8, 15, and 27 (specifically D-Ala2, Gln8, Ala15, and Leu27). These modifications resist DPP-IV cleavage, extending the half-life to approximately 30 minutes in rodent models while maintaining selective affinity for the GHRH receptor. Unlike CJC-1295 with DAC (Drug Affinity Complex), which incorporates a maleimidopropionic acid linker to bind serum albumin for multi-day half-lives, CJC-1295 (No DAC) retains a shorter, pulsatile profile that closely mirrors natural physiological GHRH release. High-purity batches of CJC-1295 (No DAC) are synthesized using solid-phase peptide synthesis (SPPS) and verified for chemical integrity.

Molecular Structure & Pharmacological Profile of PT-141

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It was developed as a downstream metabolite of the synthetic melanocortin receptor agonist Melanotan II. During preclinical investigations of skin pigmentation, researchers observed that Melanotan II elicited central nervous system responses independent of melanocyte stimulation. Subsequent structural refinement isolated PT-141 by removing the lipophilic tail, eliminating pigment-stimulating activity while retaining potent activity at central melanocortin receptors.

Unlike CJC-1295 (No DAC), which operates exclusively within the anterior pituitary GHRH signaling system, PT-141 is a non-selective agonist of melanocortin sub-types, demonstrating primary binding affinity for MC3R and MC4R located in the hypothalamus and preoptic area. Its cyclic structure provides high resistance to proteolytic degradation, yielding an in vivo half-life of 1.5 to 2 hours in standard preclinical rodent assays.

Receptor Binding and Signal Transduction Pathways

The signal transduction cascades triggered by these two peptides diverge significantly at the cellular level. When CJC-1295 (No DAC) binds to the G-protein coupled GHRH receptor on somatotropes in the anterior pituitary, it activates the Gs alpha subunit. This stimulates membrane-bound adenylate cyclase, causing an intracellular increase in cyclic adenosine monophosphate (cAMP). High cAMP levels activate protein kinase A (PKA), which triggers voltage-gated calcium channels, promoting exocytosis of stored growth hormone into circulation.

Conversely, PT-141 binds to melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors located on post-synaptic neurons in the central nervous system. Activation of MC4R stimulates adenylate cyclase and phospholipase C pathways within hypothalamic neural networks. This central activation modulates downstream autonomic nervous system signaling, altering neurochemical responses without initiating the somatotropic cascade associated with GHRH analogs.

Preclinical Literature: CJC-1295 (No DAC) Research

In preclinical literature, CJC-1295 (No DAC) functions primary as a GHRH analog. Preclinical studies suggest it operates as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research, cellular differentiation studies, and metabolic secretagogue investigations.

Rodent assays demonstrate that CJC-1295 (No DAC) preserves normal pulsatile growth hormone secretion patterns when administered in discrete intervals, avoiding the continuous receptor down-regulation or desensitization sometimes observed with uninterrupted GH exposure. In vitro data indicate that supernatant IGF-1 concentrations increase proportionally following GHRH receptor stimulation, making CJC-1295 (No DAC) an important benchmark compound for studying muscle cell proliferation, collagen synthesis, and osteoblast activity in animal models.

Preclinical Literature: PT-141 (Bremelanotide) Research

Preclinical research involving PT-141 centers primarily on its capacity to cross the blood-brain barrier and bind hypothalamic MC4R complexes. In animal models, researchers utilize PT-141 to map central melanocortin circuits involved in autonomic motor pathways, motivational behaviors, and neurovascular signaling.

Unlike nitric oxide donors or vasoactive agents that alter peripheral smooth muscle directly, in vivo rodent studies confirm that PT-141 acts centrally. Microinjection of PT-141 into the medial preoptic area (mPOA) of the hypothalamus induces measurable neurochemical downstream activity, making it a critical research tool for neurobiologists investigating central melanocortinergic control over peripheral physiology.

Comparative Class Analysis: GHRH Peptides vs. Melanocortin Agonists

When evaluating growth-factor axis modifiers alongside CJC-1295 (No DAC), researchers frequently examine co-administration protocols with ghrelin mimetics like ipamorelin or earlier GHRH analogs such as sermorelin and tesamorelin. In contrast, PT-141 belongs strictly to the melanocortinergic system, sharing structural homology with melanotan 2 while lacking the potent melanocyte-stimulating properties observed in skin pigmentation studies.

Because GHRH analogs and melanocortin agonists possess completely distinct primary structures and physiological targets, substituting one for the other in an experimental design is scientifically invalid. Research designs targeting somatotropic endocrine output, protein synthesis mechanisms, or insulin-like growth factor responses require GHRH or GHRP compounds, whereas studies focused on central nervous system receptor mapping demand melanocortin pathway selective ligands.

Selecting the Appropriate Compound for Study Designs

Choosing between CJC-1295 (No DAC) and PT-141 depends entirely on the primary hypothesis of the research project. For laboratories exploring pituitary signaling, growth factor regulation, or cellular turnover, CJC-1295 (No DAC) provides a predictable model of pulsatile GHRH receptor stimulation.

For laboratories investigating neurochemical pathways, hypothalamic receptor distribution, or melanocortin-mediated central responses, PT-141 is the appropriate candidate. Research teams can review compound specifications in our research library or establish institutional accounts via our wholesale portal for bulk raw material procurement.

Laboratory Reconstitution, Handling, and Quality Standards

Both CJC-1295 (No DAC) and PT-141 are supplied as lyophilized powders sealed under inert gas to preserve peptide integrity. For laboratory preparation, lyophilisates should be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol). Gently dilute down the side of the glass vial to prevent mechanical agitation and shearing of the peptide chains. Use our online reconstitution calculator to determine precise molar concentrations and volume calculations for micro-pipetting.

PX1 Research enforces strict quality assurance protocols for every lot. All peptides are manufactured in GMP-compliant facilities within the USA and undergo rigorous analytical verification in ISO 17025 accredited testing environments. Every batch is evaluated via High-Performance Liquid Chromatography (HPLC) for chemical purity (exceeding 99%) and Mass Spectrometry (MS) for sequence mass confirmation. Furthermore, endotoxin testing ensures reagents meet strict limits for cell culture and in vitro application. Researchers can independently verify lot details by reviewing a published Certificate of Analysis (COA).